Genotyping Performed by FRET-PCR Without DNA Extraction
|
By LabMedica International staff writers Posted on 07 Jul 2014 |

Image: The LightCycler 2.0 real-time polymerase chain reaction analyzer and centrifuge (Photo courtesy of Roche).”

Image: The Scepter 2.0 Automated Cell Counter (Photo courtesy of Merck Millipore).
Blood samples are extensively used for the molecular diagnosis of many hematological diseases using a variety of techniques, based on the amplification of nucleic acids.
Current methods for polymerase chain reaction (PCR) use purified genomic DNA, mostly isolated from total peripheral blood cells or white blood cells (WBC), which can be improved by a real-time fluorescence resonance energy transfer-based method for genotyping directly from blood cells.
Hematologists at the Hospital Universitari Son Espases (Palma de Mallorca, Spain) studied peripheral blood from 34 patients collected into tubes containing ethylenediaminetetraacetic acid (EDTA). Among the samples, they included a mixture of mutant alleles for patients suffering from thrombosis or hereditary hemochromatosis. Red blood cells (RBCs) were lysed and white blood cells (WBCs) isolated. A real-time PCR was then performed followed by a melting curve analysis for different genes including methylenetetrahydrofolate reductase (MTHFR), hemochromatosis (HFE), coagulation factor V Leiden (F5), prothrombin factor two (F2) and coagulation factor XII (F12).
The real time PCR was performed on the LightCycler 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN, USA). In order to standardize the samples for the real-time PCR reaction, cells were counted in a Scepter 2.0 Automated Cell Counter (Merck Millipore, Billerica, MA, USA) and adjusted to 5×106 cells/mL. After testing 34 samples comparing the real-time crossing point (CP) values between 5×106 WBC/mL and 20 ng/µL of purified DNA, the results for F5 Leiden were as follows: CP mean value for WBC was 29.26 ± 0.57 versus purified DNA 24.79 ± 0.56. There was an observed delay of about four cycles when PCR was performed from WBC instead of DNA.
The authors concluded that their protocol obviates the DNA purification stage, thereby saving time and resources. Furthermore, since the manipulation performed on the sample is minimal, it may decrease the risk of contamination. As they reported the results from a variety of genes, they contend that their protocol will be suitable for the genotyping of almost any inherited polymorphism. The study was published on June 25, 2014, in the Journal of Blood Medicine.
Related Links:
Hospital Universitari Son Espases
Roche Diagnostics Corporation
Merck Millipore
Current methods for polymerase chain reaction (PCR) use purified genomic DNA, mostly isolated from total peripheral blood cells or white blood cells (WBC), which can be improved by a real-time fluorescence resonance energy transfer-based method for genotyping directly from blood cells.
Hematologists at the Hospital Universitari Son Espases (Palma de Mallorca, Spain) studied peripheral blood from 34 patients collected into tubes containing ethylenediaminetetraacetic acid (EDTA). Among the samples, they included a mixture of mutant alleles for patients suffering from thrombosis or hereditary hemochromatosis. Red blood cells (RBCs) were lysed and white blood cells (WBCs) isolated. A real-time PCR was then performed followed by a melting curve analysis for different genes including methylenetetrahydrofolate reductase (MTHFR), hemochromatosis (HFE), coagulation factor V Leiden (F5), prothrombin factor two (F2) and coagulation factor XII (F12).
The real time PCR was performed on the LightCycler 2.0 Instrument (Roche Diagnostics Corporation, Indianapolis, IN, USA). In order to standardize the samples for the real-time PCR reaction, cells were counted in a Scepter 2.0 Automated Cell Counter (Merck Millipore, Billerica, MA, USA) and adjusted to 5×106 cells/mL. After testing 34 samples comparing the real-time crossing point (CP) values between 5×106 WBC/mL and 20 ng/µL of purified DNA, the results for F5 Leiden were as follows: CP mean value for WBC was 29.26 ± 0.57 versus purified DNA 24.79 ± 0.56. There was an observed delay of about four cycles when PCR was performed from WBC instead of DNA.
The authors concluded that their protocol obviates the DNA purification stage, thereby saving time and resources. Furthermore, since the manipulation performed on the sample is minimal, it may decrease the risk of contamination. As they reported the results from a variety of genes, they contend that their protocol will be suitable for the genotyping of almost any inherited polymorphism. The study was published on June 25, 2014, in the Journal of Blood Medicine.
Related Links:
Hospital Universitari Son Espases
Roche Diagnostics Corporation
Merck Millipore
Latest Molecular Diagnostics News
- Blood Gene Expression Fluctuates More Than Expected Over Time
- Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
- Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
- Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
- Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








